Barinthus Biotherapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRNS research report →
Range $3 – $3
Price Chart
About the company
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
- CEO
- William James Enright
- IPO
- 2021
- Employees
- 14
- HQ
- Germantown, MD, US
Get TickerSpark's AI analysis on BRNS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.23M
- P/E
- -0.72
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.53
- EV/EBITDA
- 0.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.18%
- ROIC
- -61.15%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-5,858,659-139.1%
- Op Income
- $-54,194,349
- Net Income
- $-66,583,233-9.0%
- EPS
- $-1.64-5.8%
- OCF Growth
- -65.8%
- FCF Growth
- -61.0%
- 52W High
- $1.83
- 52W Low
- $0.51
- 50D MA
- $0.65
- 200D MA
- $0.66
- Beta
- -0.36
- RSI (14)
- 60
- Avg Volume
- 49.74K
No earnings-call transcripts are available for BRNS yet.
- Free Float
- 96.5%
- Shares Outstanding
- 40.85M
- Float Shares
- 39.43M
Buy/sell ratio 0.02. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 9, 26 | Oxford Science Enterprises plc | other | 8,797,770 |
| Sep 9, 26 | Wright Robin | sell | 18,604 |
| Sep 9, 26 | Wright Robin | sell | 19,197 |
| Sep 9, 26 | Wright Robin | sell | 19,516 |
| Sep 9, 26 | Wright Robin | sell | 20,174 |
| Sep 9, 26 | Wright Robin | sell | 48,256 |
| Sep 9, 26 | Wright Robin | sell | 20,394 |
| Sep 9, 26 | Wright Robin | sell | 34,328 |
| Sep 9, 26 | Scheeren Joseph | sell | 23,000 |
| Sep 9, 26 | Scheeren Joseph | sell | 34,328 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BRNS coverage
Recent articles, reports, and earnings notes.
No research on BRNS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BRNS report →Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year?
zacks.com · Sep 7
Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics
globenewswire.com · Aug 24
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
globenewswire.com · Aug 6
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders?
prnewswire.com · May 12
Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
businesswire.com · May 11
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
globenewswire.com · Apr 30
Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders?
prnewswire.com · Mar 16
Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Grows By 72.8%
defenseworld.net · Jan 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.